Protective effect of ulinastatin on myocardial injuries in children with severe pneumonia
AJTR Copyright © 2023..
BACKGROUND: This study aimed to investigate the effect of ulinastatin on myocardial protection in children with severe pneumonia.
METHODS: In this retrospective study, children with severe pneumonia were divided into two groups based on their treatment methods. The control group (n=39) received anti-infection therapy, while the experimental group (n=43) received anti-infection therapy combined with ulinastatin. The clinical treatment efficacy, levels of peripheral inflammatory factors, T lymphocyte subsets, QT dispersion and adverse reactions of the two groups were observed and compared before and after treatment.
RESULTS: The clinical efficacy was improved after intervention (P<0.05), and the total response rate was 88.4% (38/43) in the experimental group and 64.1% in the control group. The post-treatment levels of interleukin-8 (IL-8), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) in the peripheral blood were lower than those before treatment, with significant differences (P<0.05). After treatment, the serum levels of CD3+, CD4+ and CD4+/CD8+ in the experimental group were significantly higher than those in the control group, whereas the levels of IL-6, IL-8 and hscRP in the peripheral blood were lower in the experimental group than those in the control group, with significant differences (P<0.05). The QT dispersion indexes, such as QTmax, QTmin, QTd, QTcmax, QTcd and QTcmin in the experimental group were shorter than those in the control group (P<0.05).
CONCLUSION: Ulinastatin has significant therapeutic efficacy and safety in the clinical treatment of children with severe pneumonia, which may be related to inhibition of the release of inflammatory factors, shortened QT dispersion and the improvement of immune function of peripheral blood T lymphocyte subsets.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
American journal of translational research - 15(2023), 3 vom: 18., Seite 2006-2015 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fan, Xiaoying [VerfasserIn] |
|---|
| Themen: |
Anti-infection |
|---|
| Anmerkungen: |
Date Revised 15.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM355611740 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355611740 | ||
| 003 | DE-627 | ||
| 005 | 20231226064718.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355611740 | ||
| 035 | |a (NLM)37056839 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fan, Xiaoying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protective effect of ulinastatin on myocardial injuries in children with severe pneumonia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a AJTR Copyright © 2023. | ||
| 520 | |a BACKGROUND: This study aimed to investigate the effect of ulinastatin on myocardial protection in children with severe pneumonia | ||
| 520 | |a METHODS: In this retrospective study, children with severe pneumonia were divided into two groups based on their treatment methods. The control group (n=39) received anti-infection therapy, while the experimental group (n=43) received anti-infection therapy combined with ulinastatin. The clinical treatment efficacy, levels of peripheral inflammatory factors, T lymphocyte subsets, QT dispersion and adverse reactions of the two groups were observed and compared before and after treatment | ||
| 520 | |a RESULTS: The clinical efficacy was improved after intervention (P<0.05), and the total response rate was 88.4% (38/43) in the experimental group and 64.1% in the control group. The post-treatment levels of interleukin-8 (IL-8), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) in the peripheral blood were lower than those before treatment, with significant differences (P<0.05). After treatment, the serum levels of CD3+, CD4+ and CD4+/CD8+ in the experimental group were significantly higher than those in the control group, whereas the levels of IL-6, IL-8 and hscRP in the peripheral blood were lower in the experimental group than those in the control group, with significant differences (P<0.05). The QT dispersion indexes, such as QTmax, QTmin, QTd, QTcmax, QTcd and QTcmin in the experimental group were shorter than those in the control group (P<0.05) | ||
| 520 | |a CONCLUSION: Ulinastatin has significant therapeutic efficacy and safety in the clinical treatment of children with severe pneumonia, which may be related to inhibition of the release of inflammatory factors, shortened QT dispersion and the improvement of immune function of peripheral blood T lymphocyte subsets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Myocardial injuries | |
| 650 | 4 | |a T lymphocyte subsets | |
| 650 | 4 | |a anti-infection | |
| 650 | 4 | |a severe pneumonia | |
| 650 | 4 | |a ulinastatin | |
| 700 | 1 | |a Zhang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jintao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of translational research |d 2009 |g 15(2023), 3 vom: 18., Seite 2006-2015 |w (DE-627)NLM193229463 |x 1943-8141 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:3 |g day:18 |g pages:2006-2015 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 3 |b 18 |h 2006-2015 | ||